Vestcor Inc Sells 5,200 Shares of Novo Nordisk A/S (NYSE:NVO)

Vestcor Inc lessened its position in shares of Novo Nordisk A/S (NYSE:NVO) by 40.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,800 shares of the company’s stock after selling 5,200 shares during the quarter. Vestcor Inc’s holdings in Novo Nordisk A/S were worth $929,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. 1620 Investment Advisors Inc. purchased a new stake in shares of Novo Nordisk A/S during the second quarter worth about $25,000. Strategic Investment Solutions Inc. IL purchased a new stake in Novo Nordisk A/S during the 2nd quarter worth approximately $25,000. Gilliland Jeter Wealth Management LLC increased its stake in Novo Nordisk A/S by 200.0% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after purchasing an additional 120 shares in the last quarter. Daiwa Securities Group Inc. purchased a new position in shares of Novo Nordisk A/S in the third quarter worth $28,000. Finally, Abound Wealth Management grew its holdings in shares of Novo Nordisk A/S by 257.4% during the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock valued at $31,000 after buying an additional 157 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on NVO shares. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Buy” and an average price target of $150.40.

Novo Nordisk A/S Trading Down 2.7 %

Novo Nordisk A/S stock opened at $108.63 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The firm has a market cap of $487.48 billion, a PE ratio of 35.16, a P/E/G ratio of 1.43 and a beta of 0.40. The stock’s 50 day simple moving average is $110.88 and its two-hundred day simple moving average is $126.60. Novo Nordisk A/S has a 12 month low of $96.53 and a 12 month high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.